Network pharmacology and experimental verification to decode the action of Qing Fei Hua Xian Decotion against pulmonary fibrosis

• Published in: PloS one Vol. 19; no. 6; p. e0305903
• Main Authors: Ke, Hao-Liang, Li, Rui-Jie, Yu, Chao-Chao, Wang, Xiu-Ping, Wu, Chao-Yan, Zhang, Ying-Wen
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 24.06.2024; Public Library of Science (PLoS)
• Subjects: 1-Phosphatidylinositol 3-kinase; AKT protein; Animals; Bioinformatics; Biology and Life Sciences; Bleomycin; Chemical compounds; Chinese medicine; Computed tomography; Computer and Information Sciences; COVID-19; COVID-19 - metabolism; COVID-19 Drug Treatment; Drugs, Chinese Herbal - pharmacology; Drugs, Chinese Herbal - therapeutic use; Epithelial-Mesenchymal Transition - drug effects; Extracellular matrix; Fibrosis; Gelatinase B; Genes; Herbal medicine; Humans; Inflammation; Laboratory animals; Lung diseases; Male; Medicine and Health Sciences; Medicine, Chinese Traditional - methods; Network analysis; Network Pharmacology; NF-κB protein; Pharmaceuticals; Pharmacology; Prednisone; Protein Interaction Maps - drug effects; Proteins; Pulmonary fibrosis; Pulmonary Fibrosis - chemically induced; Pulmonary Fibrosis - drug therapy; Pulmonary Fibrosis - metabolism; Pulmonary Fibrosis - pathology; Rats; Rats, Sprague-Dawley; Signal Transduction - drug effects; Smad2 protein; Staining; Stat3 protein; Therapeutic targets; Traditional Chinese medicine; Transforming Growth Factor beta1 - metabolism; Transforming growth factor-b1; Verification; China

Pulmonary fibrosis (PF) is a common interstitial pneumonia disease, also occurred in post-COVID-19 survivors. The mechanism underlying the anti-PF effect of Qing Fei Hua Xian Decotion (QFHXD), a traditional Chinese medicine formula applied for treating PF in COVID-19 survivors, is unclear. This stud...